Tag
The BioTAK score, a novel biomarker-driven diagnostic tool, accurately discriminates Takotsubo syndrome from acute coronary syndrome pre-angiography, streamlining diagnostic pathways and potentially reducing invasive procedures.
A large UK randomized trial found that routine outpatient CT coronary angiography after ruling out myocardial infarction in suspected acute coronary syndrome did not reduce the risk of subsequent cardiac events compared to standard care.
The ICare-FASTER trial demonstrates that implementing point-of-care high-sensitivity cardiac troponin testing in emergency departments safely reduces patient length of stay by nearly 50 minutes without compromising 30-day cardiac safety out
This randomized trial evaluates the safety and efficiency of the ESC 0/1-hour versus 0/3-hour high-sensitivity troponin pathways in suspected acute coronary syndrome, showing noninferior safety but no significant improvement in rapid discha
A nationwide Chinese study reveals that exposure to tropical cyclones increases acute coronary syndrome risk by 14%, delays treatment times, and disproportionately affects vulnerable populations. Coordinated public health and clinical strat
The BRIDGE trial demonstrates that protocol-driven early intensive lipid-lowering therapy significantly improves guideline-recommended LDL-C target attainment in acute coronary syndrome patients, fostering better cardiovascular risk control
This study introduces a causal endotype-based classification of myocardial infarction, revealing distinct underlying mechanisms and clinical outcomes beyond the traditional type 1/type 2 framework, potentially improving MI diagnosis and man
JCAD, a junctional protein, independently predicts major adverse cardiovascular events (MACE) in acute coronary syndrome (ACS) patients with residual lipid and inflammatory risks, suggesting a key role in coagulation and fibrinolysis and a
The LEGEND trial demonstrates that a high-sensitivity troponin-based rule-out strategy significantly reduces hospital length of stay and cardiac testing while safely excluding acute myocardial infarction in emergency department patients.
A comprehensive meta-analysis of over 22 million individuals identifies mental disorders, particularly PTSD and sleep disturbances, as major independent risk factors for acute coronary syndrome, urging a paradigm shift toward integrated car
A landmark analysis from the NEOMINDSET trial demonstrates that while potent P2Y12 inhibitor monotherapy reduces bleeding, it significantly increases ischemic risk in the first 30 days after PCI for acute coronary syndrome, suggesting that
A breakthrough study identifies the junctional protein associated with coronary artery disease (JCAD) as a significant predictor of recurrent cardiovascular events in ACS patients, particularly those with residual lipid and inflammatory ris
Post-hoc analysis of the TROPICAL-ACS trial demonstrates that platelet function testing-guided de-escalation of dual antiplatelet therapy from prasugrel to clopidogrel is safe and effective in ACS patients, regardless of their atherothrombo
A secondary analysis of the ODYSSEY OUTCOMES trial reveals that oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) independently predict cardiovascular risk in ACS patients, particularly when Lp(a) levels are low. Treatment with ali
A secondary analysis of the HiSTORIC trial reveals that using high-sensitivity cardiac troponin for risk stratification significantly reduces ED length of stay and increases safe discharge rates for low- and intermediate-risk patients, with
Switching from high-sensitivity troponin I to T significantly increases diagnoses of myocardial injury and hospital admissions without improving long-term cardiovascular outcomes, while low-threshold troponin I remains a safe tool for rapid
This review synthesizes current evidence on the efficacy and safety of ticagrelor combined with aspirin compared to aspirin alone following CABG for acute coronary syndrome, highlighting the 2025 TACSI trial and its implications for clinica
A large randomized clinical trial demonstrated that the 23-valent pneumococcal polysaccharide vaccine (PPV23) did not significantly reduce fatal or nonfatal acute coronary syndrome and ischemic stroke among middle-aged adults at increased c
In high bleeding risk patients undergoing PCI, aspirin-free prasugrel monotherapy fails to reduce major bleeding and shows increased myocardial infarction risk in ACS but not non-ACS patients, suggesting selective use post-PCI.
STOPDAPT-3 trial shows aspirin and clopidogrel yield comparable cardiovascular and bleeding outcomes 1 month to 1 year post-PCI in ACS patients, regardless of bleeding risk or STEMI status.
